These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 19567209)
21. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer. Limwattananon S; Limwattananon C; Maoleekulpairoj S; Soparatanapaisal N J Med Assoc Thai; 2006 May; 89(5):690-8. PubMed ID: 16756057 [TBL] [Abstract][Full Text] [Related]
22. Rituximab for the treatment of rheumatoid arthritis. Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686 [TBL] [Abstract][Full Text] [Related]
23. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Stevenson M; Pandor A Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027 [TBL] [Abstract][Full Text] [Related]
24. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419 [TBL] [Abstract][Full Text] [Related]
25. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543 [TBL] [Abstract][Full Text] [Related]
26. Bortezomib for the treatment of multiple myeloma patients. Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211 [TBL] [Abstract][Full Text] [Related]
27. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214 [TBL] [Abstract][Full Text] [Related]
28. Capecitabine for the treatment of advanced gastric cancer. Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486 [TBL] [Abstract][Full Text] [Related]
29. Omalizumab for the treatment of severe persistent allergic asthma. Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Lee SG; Jee YG; Chung HC; Kim SB; Ro J; Im YH; Im SA; Seo JH Breast Cancer Res Treat; 2009 Apr; 114(3):589-95. PubMed ID: 18437555 [TBL] [Abstract][Full Text] [Related]
31. Ustekinumab for the treatment of moderate to severe psoriasis. Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031 [TBL] [Abstract][Full Text] [Related]
32. Gemcitabine for the treatment of metastatic breast cancer. Jones J; Takeda A; Tan SC; Cooper K; Loveman E; Clegg A Health Technol Assess; 2009 Sep; 13 Suppl 2():1-7. PubMed ID: 19804683 [TBL] [Abstract][Full Text] [Related]
33. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Blommestein HM; Armstrong N; Ryder S; Deshpande S; Worthy G; Noake C; Riemsma R; Kleijnen J; Severens JL; Al MJ Pharmacoeconomics; 2016 Jan; 34(1):23-31. PubMed ID: 26314282 [TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer. Roy C; Choudhury KB; Pal M; Saha A; Bag S; Banerjee C Indian J Cancer; 2012; 49(3):266-71. PubMed ID: 23238142 [TBL] [Abstract][Full Text] [Related]
35. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394 [TBL] [Abstract][Full Text] [Related]
36. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718 [TBL] [Abstract][Full Text] [Related]
37. Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer. Kaltenthaler E; Tappenden P; Booth A; Akehurst R Health Policy; 2008 Sep; 87(3):389-400. PubMed ID: 18387689 [TBL] [Abstract][Full Text] [Related]
38. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804 [TBL] [Abstract][Full Text] [Related]
39. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649 [TBL] [Abstract][Full Text] [Related]
40. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]